Mr. Paterson was appointed President and Chief Executive Officer of Verastem Oncology in 2023, following more than a decade of increasing leadership roles and responsibilities within the Company since joining in 2011. He has more than 30 years of experience across oncology drug and diagnostic development, business development, and launch planning.
 

Before joining Verastem, Mr. Paterson was the co-founder and Chief Operating Officer of On-Q-ity, a developer of technology to capture and analyze circulating tumor cells, and the founding Chief Executive Officer of The DNA Repair Company (merged to form On-Q-ity), which developed oncology-focused molecular diagnostics. Prior to that, Mr. Paterson was Head of Global Strategy for Specialty Market and Patient-Level Data at IMS Health, after playing a key role in the acquisition of PharMetrics by IMS Health as Vice President, Marketing and Corporate Development. While at PharMetrics, Mr. Paterson led the development of an innovative suite of pharmaceutical product launch tools that became the basis of the company’s product line. Earlier in his career, Mr. Paterson led clinical development and regulatory initiatives in academic, industry, and Contract Research Organizations.
 

Mr. Paterson holds a Bachelor of Arts in Biology from Boston University and attended the Northeastern University Graduate Pharmacology program.